Submitted:
30 September 2024
Posted:
03 October 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Study Design and Inclusion Criteria
2.2. Data Collection
2.3. Follow-Up
2.4. Statistical Analysis
3. Results
3.1. Twenty-Eight Days Survival of Patients with ALD Cirrhosis
3.2. Prediction of 28-Day Mortality Based on Prognostic Scores-Formulation of the New LIV-IN Prognostic Score
4. Discussion
5. Conclusion
Author Contributions
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Shield KD, Parry C, Rehm J. Chronic diseases and conditions related to alcohol use. Alcohol Res. 2013;35(2):155-173.
- WORLD HEALTH ORGANIZATION. Global status report on alcohol and health 2018. World Health Organization, 2018.
- Trifan A, Minea H, Rotaru A, et al. Predictive Factors for the Prognosis of Alcoholic Liver Cirrhosis. Medicina (Kaunas). 2022;58(12):1859. [CrossRef]
- Collaborators GDAI. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222. [CrossRef]
- Wu SL, Zheng YX, Tian ZW, Chen MS, Tan HZ. Scoring systems for prediction of mortality in decompensated liver cirrhosis: A meta-analysis of test accuracy. World J Clin Cases. 2018;6(15):995-1006. [CrossRef]
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018;69(1):154-181. [CrossRef]
- D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217-231. [CrossRef]
- Kartoun U, Corey KE, Simon TG, et al. The MELD-Plus: A generalizable prediction risk score in cirrhosis. PLoS One. 2017;12(10):e0186301. [CrossRef]
- Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437.e14379. [CrossRef]
- Arroyo V, Angeli P, Moreau R, et al. The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. J Hepatol. 2021;74(3):670-685. [CrossRef]
- Chiriac S, Stanciu C, Singeap AM, Sfarti CV, Cuciureanu T, Trifan A. Prognostic value of neutrophil-to-lymphocyte ratio in cirrhotic patients with acute-on-chronic liver failure. Turk J Gastroenterol. 2020;31(12):868-876. [CrossRef]
- Toyoda H, Johnson PJ. The ALBI score: From liver function in patients with HCC to a general measure of liver function. JHEP Rep. 2022;4(10):100557. [CrossRef]
- Tonon M, Angeli P, Piano S. Bacterial infections in cirrhosis. Infect Microb Dis 2021;3(3):117–124. [CrossRef]
- Ministry of Health of the Republic of Serbia. National Guide to Good Clinical Practice for the Diagnosis and Treatment of Alcoholism. Belgrade, 2013. Avaliable from https://www.zdravlje.gov.rs/view_file.php?file_id=544&cache=sr.
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-460. [CrossRef]
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatic encephalopathy J Hepatol. 2022;77(3):807-824. [CrossRef]
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on acute-on-chronic liver failure. J Hepatol. 2023;79(2):461-491. [CrossRef]
- Lin S, Agarwal B, Kumar R, Jalan R, Mehta G. Defining the prognosis of critically ill patients with alcohol-related liver disease. J Hepatol. 2021;75(4):986-987. [CrossRef]
- Kulkarni S, Sharma M, Rao PN, Gupta R, Reddy DN. Acute on Chronic Liver Failure-In-Hospital Predictors of Mortality in ICU. J Clin Exp Hepatol. 2018;8(2):144-155. [CrossRef]
- da Silva Boteon APC, Chauhan A, Boteon YL, et al. Predictive factors for 28-day mortality in acute-on-chronic liver failure patients admitted to the intensive care unit. Dig Liver Dis. 2019;51(10):1416-1422. [CrossRef]
- Thanapirom K, Teerasarntipan T, Treeprasertsuk S, et al. Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure. Hepatol Int. 2022;16(1):171-182. [CrossRef]
- Al Kaabi H, Al Alawi AM, Al Falahi Z, Al-Naamani Z, Al Busafi SA. Clinical Characteristics, Etiology, and Prognostic Scores in Patients with Acute Decompensated Liver Cirrhosis. J Clin Med. 2023;12(17):5756. [CrossRef]
- Jeong JH, Lee SB, Sung A, Shin H, Kim DH. Factors predicting mortality in patients with alcoholic liver cirrhosis visiting the emergency department. Medicine (Baltimore). 2023;102(8):e33074. [CrossRef]
- Sano F, Ohira T, Kitamura A, et al. Heavy alcohol consumption and risk of atrial fibrillation. The Circulatory Risk in Communities Study (CIRCS). Circ J. 2014;78(4):955-961. [CrossRef]
- Bolarín JM, Pérez-Cárceles MD, Hernández Del Rincón JP, et al. Causes of Death and Survival in Alcoholic Cirrhosis Patients Undergoing Liver Transplantation: Influence of the Patient’s Clinical Variables and Transplant Outcome Complications. Diagnostics (Basel). 2021;11(6):968. [CrossRef]
- Liu LX, Zhang Y, Nie Y, Zhu X. Assessing the Prediction Effect of Various Prognosis Model for 28-Day Mortality in Acute-on-Chronic Liver Failure Patients. Risk Manag Healthc Policy. 2020;13:3155-3163. [CrossRef]
- Маткoвська НР. Analysis of Causes of Death in Patients with Alcoholic Liver Cirrhosis Associated with Non-alcoholic Fatty Liver Disease. 2019;(4):47-50.
- Park JE, Chung KS, Song JH, Kim SY, Kim EY, Jung JY, Kang YA, Park MS, Kim YS, Chang J, Leem AY. The C-Reactive Protein/Albumin Ratio as a Predictor of Mortality in Critically Ill Patients. J Clin Med. 2018; 8;7(10):333. [CrossRef]
- Kulkarni S, Sharma M, Rao PN, Gupta R, Reddy DN. Acute on Chronic Liver Failure-In-Hospital Predictors of Mortality in ICU. J Clin Exp Hepatol. 2018;8(2):144-155. [CrossRef]
- Jalan R, Pavesi M, Saliba F, et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol. 2015;62(4):831-840. [CrossRef]
- Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038-1047. [CrossRef]
- Antkowiak M, Gabr A, Das A, et al. Prognostic Role of Albumin, Bilirubin, and ALBI Scores: Analysis of 1000 Patients with Hepatocellular Carcinoma Undergoing Radioembolization. Cancers (Basel). 2019;11(6):879. [CrossRef]
- Liu LX, Zhang Y, Nie Y, Zhu X. Assessing the Prediction Effect of Various Prognosis Model for 28-Day Mortality in Acute-on-Chronic Liver Failure Patients. Risk Manag Healthc Policy. 2020;13:3155-3163. [CrossRef]
- Emenena I, Emenena B, Kweki AG, et al. Model for End Stage Liver Disease (MELD) Score: A Tool for Prognosis and Prediction of Mortality in Patients With Decompensated Liver Cirrhosis. Cureus. 2023;15(5):e39267. [CrossRef]
- Okonkwo U, Nwosu M, Bojuwoye B. The Predictive Values Of The Meld And Child-Pugh Scores In Determining Mortality From Chronic Liver Disease Patients In Anambra State, Nigeria.. The Internet Journal of Gastroenterology. 2010;10:2.
- Brown C, Aksan N, Muir AJ. MELD-Na Accurately Predicts 6-Month Mortality in Patients With Decompensated Cirrhosis: Potential Trigger for Hospice Referral. J Clin Gastroenterol. 2022;56(10):902-907. [CrossRef]
- Weiss E, de la Peña-Ramirez C, Aguilar F, et al. Sympathetic nervous activation, mitochondrial dysfunction and outcome in acutely decompensated cirrhosis: the metabolomic prognostic models (CLIF-C MET). Gut. 2023;72(8):1581-1591. [CrossRef]
- Borgonovo A, Baldin C, Maggi DC, et al. Systemic Inflammatory Response Syndrome in Patients Hospitalized for Acute Decompensation of Cirrhosis. Can J Gastroenterol Hepatol. 2021;2021:5581587. [CrossRef]
- Parlet CP, Kavanaugh JS, Horswill AR, Schlueter AJ. Chronic ethanol feeding increases the severity of Staphylococcus aureus skin infections by altering local host defenses. J Leukoc Biol. 2015;97(4):769-778. [CrossRef]
- Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9(9):727-738. [CrossRef]
- Ledesma Castaño F, Echevarria Vierna S, Lozano Polo JL, Oloriz Rivas R, Alvarez Moreno C, Pons Romero F. Interleukin-1 in alcoholic cirrhosis of the liver: the influence of nutrition. Eur J Clin Nutr. 1992;46(7):527-533.
- Chan C, Levitsky J. Infection and Alcoholic Liver Disease. Clin Liver Dis. 2016;20(3):595-606. [CrossRef]
- Khedher S, Fouthaili N, Maoui A, Lahiani S, Salem M, Bouzid K. The Diagnostic and Prognostic Values of C-Reactive Protein and Procalcitonin during Bacterial Infections in Decompensated Cirrhosis. Gastroenterol Res Pract. 2018;2018:5915947. [CrossRef]




| Total | AD | ACLF | p | |
|---|---|---|---|---|
| n | 145 | 107 | 38 | |
| Age (years)✕ | 56.42±10.87 | 57.07±10.81 | 54.6±10.98 | 0.232 |
| Gender (m/f) (%) | 129/16 (88.9/11.3) | 99/8 (92.5/7.5) | 30/8 (78.9/21.1) | 0.03 |
| Active alcohol consumption (Yes/No) (%) | 123/22( 84.8/15.2) | 88/19 (82.8/17.8) | 35/3 (92.1/7.9) | 0.192 |
| ICU Yes/ No (%) | 83/62(57.2/42.8) | 55/52 (51.4/48.6) | 28/10 (73.7/26.3) | 0.02 |
| Ascites Yes/No (%) Grade n, (%): 1 2 3 |
117/28(80.7/19.3) 32 (27.3) 30 (25.64) 55 (47) |
81/26(75.7/24.3) 27 (33.3) 24 (29.6) 30 (37) |
36/2 (94.7/5.3) 5 (13.9) 6 (16.7) 25 (69.4) |
0.009 |
| HE Yes/No (%) Type: Covert (n/%) Overt (n/%) |
97/48(66.9/33.1) 12(12.4) 85 (87.6) |
64/43 (59.8/40.2) 6 (9.4) 58 (90.6) |
33/5 (86.8/13.2) 6 (18.1) 27 (81.8) |
0.02 |
| HRS Yes/No (%) | 19/125(13.2/86.8) | 9/97(8.5/91.5) | 10/28 (26.3/3.7) | 0.01 |
| SIRS Yes/No (%) | 38/107(26.2/73.8) | 23/84(21.49/82.24) | 15/23(39.47/60.5) | 0.03 |
| UGIB Yes/No (%) Bleeding focus n (%): Variceal Ulcer Other |
55/90 (37.9/62.1) 31 (56.4) 4 (7.3) 20 (36.4%) |
43/64 (40.2/59.8) 26 (60.45) 3 (6.97) 14 (32.5) |
12/26 (31.6/68.4) 5 (41.67) 1 (8.3) 6 (50) |
0.43 |
| Variables | Total study group | AD | ACLF | p |
|---|---|---|---|---|
| WBC (x109/l)a | 9.6 (7.1-15.2) | 8.2(6.8-12.35) | 14.6 (10.6-17.63) | <0.01 |
| Plt (x109/l)a | 98 (65-138) | 98(65-124.5) | 100 (70-149.75) | 0.39 |
| Hb (g/l)b | 97.05±25 | 99.1±24.67 | 91.55±25.44 | 0.1 |
| Total bilirubin (µmol/l)a | 61.6 (28-148.7) | 49.1(25.1-101.8) | 154.15 (73.27-391.1) | <0.01 |
| Creatinine (µmol/l)a | 78 (65-138) | 74(63.5-113.5) | 133.5 (73-179.5) | 0.01 |
| Albumin(g/l)b | 27.5±5.71 | 28.57±5.76 | 24.5±4.43 | <0.01 |
| CRP (mg/l)a | 20 (7.1-78.4) | 10.7(5.15-64.15) | 10.7 (5.15-64.15) | <0.01 |
| Procalcitonin (ng/l)a | 0.44 (0.17-0.8) | 0.24 (0.1-0.7) | 0.635 (0.49-0.88) | <0.01 |
| Fibrinogen(g/l)a | 2.8 (1.9-3.3) | 2.5(1.85-3.2) | 3.15 (2.62-3.87) | 0.01 |
| PT (s)a | 16.6 (14.9-20.6) | 16.1(14.75-19.6) | 19.95 (16.05-26.05) | <0.01 |
| INR a | 1.5 (1.3-1.9) | 1.44 (1.28-1.81) | 1.73 (1.45-2.4) | <0.01 |
| Total | AD | ACLF | p | ||
|---|---|---|---|---|---|
| Community-acquired infection, n (%) | 45(31.03) | 32 (29.9) | 13 (34.2) | 0.07 | |
| Infection focus, n (%): | 21 (46.7) 14 (31.1) 4 (8.9) 4 (8.9) 1 (2.2) 1 (2.2) |
18 (56.2) 8 (25) 2 (6.2) 3 (9.4) 1 (3.1) / |
3 (23.1) 6 (46.2) 2 (15.4) |
||
| UTI Pneumonia UTI and pneumonia Bacteremia Acute cholecystitis SBP |
|||||
| 1 (7.7) | |||||
| / 1 (7.7) |
|||||
| Healthcare-associated infection, n (%) | 63 (43.4) | 41 (38.3) | 22 (57.9) | 0.05 | |
| Infection focus, n (%) | 35 (55.6) 20 (31.7) 5 (7.9) 2 (3.2) 1 (1.6) |
25 (61) 10 (24.4) 4 (9.8) 1 (2.4) 1 (2.4) |
10 (45.5) 10 (45.5) 1 (4.5) 1 (4.5) / |
||
| UTI bacteremia pneumonia SBP UTI and pneumonia |
|||||
| All patients (n=46) | AD (n=24) | ACLF (n=22) | |
|---|---|---|---|
| Variceal bleeding, n (%) | 7 (15.2) | 4 (16.7) | 3 (13.6) |
| Sepsis, n (%) | 5 (10.2) | 2 (8.3) | 3 (13.6) |
| Lung failure, n (%) | 13 (28.3) | 4 (16.7) | 9 (40.9) |
| Heart failure, n (%) | 17 (37) | 10 (41.7) | 7 (31.8) |
| Cerebrovascular insult, n (%) | 1 (2.2) | 1 (4.2) | / |
| Other liver-related deaths, n (%) | 3 (6.5) | 3 (12.5) | / |
| Variables | Univariante analysis | p | Multivariate analysis | p |
|---|---|---|---|---|
| Odds ratio ( CI 95%) | Odds ratio ( CI 95%) | |||
| HE | 4.912(1.907-12.653) | 0.01 | 3.63(1.068-12.340) | 0.04 |
| CAI | 2.3(1.12-4.723) | 0.023 | 0.409 | |
| Ascites | 7.836(1.773-34.63) | 0.007 | 6.896(1.136-41.861) | 0.036 |
| HRS | 6.040 (2.122-17.191) | 0.001 | 0.08 | |
| SIRS | 8.775(3.784-20.348) | <0.01 | 9.232(3.329-26.605) | <0.01 |
| ACLF | 7.25(3.089-17.018) | <0.01 | 3.539(1.306-9.591) | 0.013 |
| Variable | All patients | AD | ACLF | p | |
|---|---|---|---|---|---|
| MELD1 | 20.08±8.242 | 17.73±7.014 | 26.66±7.913 | <0.01 | |
| MELD Na1 | 22.17±8.452 | 19.89±7.58 | 28.55±7.5 | <0.01 | |
| NLR1 | 58±5.81 | 5.39±7.62 | 6.95±6.409 | 0.265 | |
| ALBI1 | -1.24±0.729 | -1.37±0.64 | -0.87±0.704 | <0.01 | |
| LIV-IN | 6.19±2.93 | 5.63±2.87 | 7.78±2.53 | <0.01 | |
| CLIF-C AD1 | / | 56.23±9.79 | / | ||
| CLIF-C ACLF1 | / | / | 53.26±7.68 | ||
| Score | AUC | P | 95% CI | (cut off) | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|---|---|
| LIV-IN | 0.734 | <0.01 | 0.650-0.818 | 5.5 | 75.6 | 53.1 |
| MELD | 0.661 | 0.02 | 0.564-0.757 | 16.5 | 75.6 | 44.8 |
| MELD-Na | 0.696 | <0.01 | 0.599-0.792 | 21.5 | 71.1 | 58.3 |
| ALBI | 0.696 | <0.01 | 0.604-0.788 | -1.5 | 84.4 | 45.8 |
| NLR | 0.608 | 0.036 | 0.510-0.706 | 2.5 | 84.4 | 34.4 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).